Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oncolytics Biotech Inc. (ONCY : NSDQ)

• Company Description    Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, one of the most common family of genetic defects leading to cancer. Number of Employees: 29

• Price / Volume Information    Yesterday's Closing Price: $0.81 Daily Weekly Monthly 20 Day Moving Average: 1,236,450 shares Shares Outstanding: 119.35 (millions) Market Capitalization: $96.62 (millions) Beta: 1.02 52 Week High: $1.51 52 Week Low: $0.33 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -25.73% -29.36% 12 Week -24.35% -30.06% Year To Date -7.38% -16.90%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4350 Executive Drive Suite 325 - San Diego,CA 92121 CAN ph: 403-670-7377 fax: 403-283-0858 jpatton@oncolytics.ca http://www.oncolyticsbiotech.com

• General Corporate Information    Officers Jared Kelly - Chief Executive Officer and Director Wayne Pisano - Director and Chairman Kirk Look - Chief Financial Officer Patricia Andrews - Director Deborah M. Brown - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 68237V103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/14/26 Share - Related Items Shares Outstanding: 119.35 Most Recent Split Date: 5.00 (0.11:1) Beta: 1.02 Market Capitalization: $96.62 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.20 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -33.33% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -14,442.84 12/31/25 - -2,185.97 09/30/25 - -822.04 ROA 03/31/26 - -321.54 12/31/25 - -243.94 09/30/25 - -192.63 Current Ratio 03/31/26 - 1.38 12/31/25 - 1.12 09/30/25 - 1.84 Quick Ratio 03/31/26 - - 12/31/25 - 1.12 09/30/25 - 1.84 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - -0.04 12/31/25 - -0.04 09/30/25 - 0.00 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - 0.00

Powered by Zacks Investment Research ©